Spectrum Pharmaceuticals, Inc. (SPPI) Stock Analysis
Verdict: AVOID
A collapsing analyst consensus and massive long-term value destruction outweigh high gross margins, making this a high-risk liquidity play.
Investment score: 18/100
Analysis as of
Is Spectrum Pharmaceuticals, Inc. stock worth reviewing? The TradeMates thesis
Spectrum Pharmaceuticals is in a state of fundamental decay, evidenced by an 8-downgrade streak and a net margin of -772% TTM. With a cash runway that likely expired or reached critical levels in mid-2023, the model sees no path to appreciation without a major M&A event or dilutive financing.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 5/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Spectrum Pharmaceuticals, Inc. opportunities and risks
What speaks for SPPI
- High Gross Margins (93%)
What speaks against SPPI
- Imminent Dilution Risk
Frequently asked questions about Spectrum Pharmaceuticals, Inc. (SPPI)
Is SPPI stock a good investment?
The TradeMates model rates Spectrum Pharmaceuticals, Inc. as AVOID with an investment score of 18/100. Spectrum Pharmaceuticals is in a state of fundamental decay, evidenced by an 8-downgrade streak and a net margin of -772% TTM. With a cash runway that likely expired or reached critical levels in mid-2023, the model sees no path to appreciation without a major M&A event or dilutive financing. This is algorithmic model output, not personal investment advice.
Is SPPI stock a buy?
The TradeMates model verdict for SPPI is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.